Curis Lifesciences
November 7, 2025 – November 11, 2025
| Price | ₹120 - ₹128 |
| GMP Rumors * | ₹0 |
|---|---|
| Lot size | 1000 |
| Issue size | ₹27.52 cr |
| Allotment | Nov 12, 2025 |
| Listing | Nov 14, 2025 |
Curis Lifesciences Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| INDIVIDUAL | 2 | 2000 | 256000 | 358 |
| sHNI | 3 | 3000 | 384000 | 34 |
| bHNI | 8 | 8000 | 1024000 | 69 |
Curis Lifesciences Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 610000 | 28.37% |
| QIB | 408000 | 18.98% |
| HNI | 308000 | 14.33% |
| INDIVIDUAL | 716000 | 33.3% |
| Market Maker | 108000 | 5.02% |
| Total | 2150000 | 100% |
Curis Lifesciences About
IPO Details
| Total Issue Size | 21,50,000 shares (aggregating up to ₹27.52 Cr) |
| Fresh Issue | 21,50,000 shares (aggregating up to ₹27.52 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 shares |
| Share Holding Post Issue | 81,84,434 shares |
| Reserved for Market Maker | 1,08,000 shares (aggregating up to ₹1.3824 Cr) |
| Market Maker | RS Wealth Management Private Limited |
Key Performance Indicators (KPI)
| KPI | Jul-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| ROE | 16.26% | 55.25% | 141.51% | 2752.56% |
| ROCE | 11.65% | 27.83% | 33.57% | 14.83% |
| Debt/ Equity | 0.8 | 0.96 | 2.91 | 16.1 |
Company Financial (In ₹Crore)
| Period Ended | 31-Jul-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|---|---|---|---|
| Assets | 56.29 | 42.53 | 33.88 | 29.75 |
| Total Income | 19.51 | 49.65 | 35.87 | 36.42 |
| Profit After Tax | 2.87 | 6.11 | 4.87 | 1.88 |
| EBITDA | 4.24 | 9.54 | 8.39 | 3.28 |
| NET Worth | 19.1 | 16.23 | 5.87 | 1.01 |
| Reserves and Surplus | 13.16 | 10.29 | 5.37 | 0.51 |
| Total Borrowing | 15.32 | 15.62 | 17.09 | 16.19 |
Peer Comparison (Valuation)
| Company | P/E (x) | CMP*(₹) | Face value (₹) |
|---|---|---|---|
| Curis Lifesciences Limited | 10.00 | ||
| Sotac Pharmaceuticals Limited | 18.3 | 128 | 10.00 |
| Lincoln Pharmaceuticals Limited | 12.21 | 528 | 10.00 |
Peer Comparison (Financial Performance)
| Company | NAV/Share (₹) | RoNW (%) | EPS (Basic) (₹) |
|---|---|---|---|
| Curis Lifesciences Limited | 27.34 | 37.62 | 10.29 |
| Sotac Pharmaceuticals Limited | 47.99 | 9.00 | 4.32 |
| Lincoln Pharmaceuticals Limited | 335.34 | 12.27 | 41.11 |
About Company
The company operates both domestically and internationally, manufacturing products under loan license, contract basis, and for its own brand marketing.
Curis Lifesciences serves over 100 corporate clients through contract manufacturing and 2 clients under its own brand in Yemen and Kenya.
Its product portfolio includes:
- General pharmaceutical tablets and capsules
- Oral liquids
- External preparations
- Sterile ophthalmic ointments
The company’s state-of-the-art manufacturing facility in Sanand, Gujarat, follows strict quality control standards to ensure high safety and efficacy.
Curis Lifesciences continues to strengthen its presence through diverse pharmaceutical formulations and customized contract manufacturing solutions.
Strength
Experienced Promoters and Strong Management Team: Led by promoters with 13–15 years of pharmaceutical industry experience and medical backgrounds, the company benefits from strategic leadership and effective day-to-day management that drives steady growth and client satisfaction.
Diverse Product Portfolio: Curis Lifesciences offers a wide range of pharmaceutical products, including tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, supported by valid manufacturing licenses (G/25/2225 and G/28/1632).
Strategically Located, WHO-GMP Certified Facility: The company’s WHO-GMP accredited plant in Sanand, Gujarat, provides strong infrastructure, skilled labor access, and global regulatory registrations in Yemen, Kenya, the Philippines, and Nigeria, ensuring quality and international reach.
Weakness
Dependence on Single Manufacturing Facility: The company’s operations are concentrated in Sanand, Ahmedabad (Gujarat), making it vulnerable to regional risks such as policy changes, natural disasters, or disruptions, which may adversely affect business and financial performance.
Regulatory Compliance and Approval Risks: Operating in a highly regulated pharmaceutical industry, any delay or failure in obtaining or renewing required approvals or regulatory changes could impact the company’s operations, strategy, and profitability.
Loan Repayment and Compliance Risk: Past delays in loan installment payments may expose the company to penalties or reputational risk despite improved internal processes, potentially affecting financial stability and goodwill.
Curis Lifesciences Lead Manager(s)
Curis Lifesciences Address
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
Curis Lifesciences Registrar
MUFG Intime India Private Limited (Link Intime)
Link Intime India Private Ltd
C 101, 247 Park,
L.B.S.Marg Vikhroli (West),
Mumbai - 400083
Curis Lifesciences Reviewers
| Reviewer | Recommendation | File |
|---|